查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933312

非何杰金氏淋巴瘤治療市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察，預測（2026-2034 年）

Non-Hodgkin Lymphoma Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 125 Pages | 商品交期: 請詢問到貨日

價格

非何杰金氏淋巴瘤 (NHL) 治療市場成長驅動因子

預計未來十年，全球非何杰金氏淋巴瘤 (NHL) 治療市場將穩定成長。該市場預計在 2025 年達到 115.9 億美元，2026 年增至 125.7 億美元，並在 2034 年達到 194.4 億美元。這意味著 2026 年至 2034 年的複合年增長率 (CAGR) 為 6.25%。北美地區在 2025 年將佔市場主導地位，市場佔有率達到 49.35%，這主要得益於 NHL 的高發病率、先進療法的引入以及完善的醫療保健基礎設施。

非何杰金氏淋巴瘤是全​​球最常見的淋巴瘤和癌症類型。這些惡性腫瘤若不及時治療可能致命。目前正在進行多項臨床試驗，旨在開發復發性和難治性非何杰金氏淋巴瘤的治療方法，這表明人們對有效療法的興趣日益濃厚。

市場驅動因素

非何杰金氏淋巴瘤治療市場的主要驅動因素是其高發生率和侵襲性。許多類型的非何杰金氏淋巴瘤在晚期之前都沒有症狀，因此早期診斷和標靶治療至關重要。臨床療效的改善和治癒率的提高進一步推動了先進療法的應用，特別是免疫療法和標靶療法。

例如，免疫療法正逐漸成為一種創新且先進的治療方法，它透過標靶機制來提高患者的存活率。 Kite Pharma/Gilead Sciences 的 Yescarta 等產品正在顯著推動該領域的成長。

此外，對復發或難治性非何杰金氏淋巴瘤 (NHL) 有效治療的需求正在推動先進療法的研發和應用，從而促進市場成長。

市場限制因子

儘管市場成長，但由於先進療法的高昂成本，尤其是在新興國家，市場仍面臨挑戰。免疫療法和 CAR-T 細胞療法的高昂成本限制了許多患者的治療機會。政府報銷限制和缺乏專門的支付機制進一步阻礙了發展中地區的市場擴張。

市場趨勢

主要市場趨勢包括研發投入的增加和先進療法的上市。在對晚期和復發性 NHL 創新療法的需求推動下，領先企業正專注於研發管線。先進的診斷技術和早期檢測改善了患者的治療效果，進一步推動了先進療法的應用。

此外，人們對 CAR-T 細胞療法和個人化醫療的興趣日益濃厚，這反映出治療方式正從傳統化療轉向更精準、更具標靶性的免疫療法。

市場區隔分析

依療法分類：

  • 預計到 2026 年，免疫療法將佔 57.45% 的市場佔有率，並在 2025 年創造 66.4 億美元的收入，這主要得益於 Yescarta 等療法的推廣。
  • 標靶療法因其精準性和療效而佔了可觀的收入。
  • 化療仍然是標準療法，但由於仿製藥的廣泛應用，其收入貢獻正在下降。
  • 其他療法包括使用皮質類固醇作為輔助治療。

依疾病類型劃分：

  • 到2026年，B細胞淋巴瘤將佔87.04%的市場佔有率，反映出其發生率高於T細胞淋巴瘤。
  • T細胞淋巴瘤是一種相對罕見的疾病，對市場的貢獻有限。

依分銷管道劃分：

  • 到2026年，醫院藥局將佔60.16%的市場佔有率，因為大多數治療需要由訓練有素的專業人員進行靜脈注射。
  • 由於口服製劑有限，零售藥局的成長將較為緩慢。
  • 由於便利性和處方服務的日益普及，線上藥局正在興起。

依地區分析

北美：預計2025年市場規模將達57.2億美元，2026年將達58億美元。這主要得益於人們對先進療法的認知度高、滲透率高以及應用廣泛。

歐洲：預計歐洲市場將以8.0%的複合年增長率顯著成長，其中英國市場規模到2026年將達到5.5億美元，德國市場規模將達到8.1億美元。 CAR-T細胞療法等新型療法將推動市場擴張。

亞太地區：由於監管部門的批准和龐大的患者群體，預計亞太地區市場將快速成長。 預計到2025年，日本市場規模將達到9.009億美元，到2026年將達到9.9億美元；中國市場規模預計將達到7.3億美元；印度市場規模預計將達到3.4億美元。

世界其他地區：拉丁美洲和中東/非洲等新興市場由於醫療保健支出和意識的提高，預計對先進療法的需求將不斷增長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇

第四章：關鍵考慮因素

  • 2025年主要國家淋巴瘤盛行率
  • 在開發產品分析
  • 主要行業趨勢
  • 主要地區的監管環境
  • 非何杰金氏淋巴瘤經濟負擔分析
  • 新產品上市
  • 非何杰金氏淋巴瘤新興療法概述淋巴瘤

第五章：全球非何杰金氏淋巴瘤治療市場分析、洞察與預測（2021-2034）

  • 主要發現/摘要
  • 市場分析、洞察與預測 - 依療法分類
    • 免疫療法
    • 標靶療法
    • 化療
    • 其他
  • 市場分析、洞察與預測 - 依疾病類型分類
    • B細胞淋巴瘤
    • T細胞淋巴瘤
  • 市場分析、洞察與預測 - 依銷售管道分類
    • 醫院藥房
    • 零售藥局和藥局
    • 線上藥房
  • 市場分析、洞察與預測 - 依區域
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美非何杰金氏淋巴瘤治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲非何杰金氏淋巴瘤治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞半島
    • 其他地區歐洲

第八章 亞太地區非何杰金氏淋巴瘤治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲非何杰金氏淋巴瘤治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章 中東與非洲非何杰金氏淋巴瘤治療市場分析洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會國家
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 主要行業趨勢
  • 全球市佔率分析（2025）
  • 競爭格局概覽
  • 主要公司比較分析
  • 公司簡介
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca
  • Bayer AG
  • Novartis AG
  • Spectrum Pharmaceuticals, Inc.
  • Bristol Myers Squibb Company
  • Janssen Pharmaceuticals, Inc.
  • Genentech, Inc.(F． Hoffmann-La Roche Ltd)
  • Merck &Co., Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Other Prominent Players

第十二章：策略建議

Product Code: FBI102642

Growth Factors of non-Hodgkin lymphoma (NHL) treatment Market

The global non-Hodgkin lymphoma (NHL) treatment market is projected to grow steadily over the next decade. In 2025, the market was valued at USD 11.59 billion, expected to rise to USD 12.57 billion in 2026 and reach USD 19.44 billion by 2034, reflecting a CAGR of 6.25% from 2026-2034. North America dominated the market with a 49.35% share in 2025, driven by the high prevalence of NHL, adoption of advanced therapies, and robust healthcare infrastructure.

Non-Hodgkin lymphomas are among the most common forms of lymphomas and cancers globally. These malignancies, if left untreated, can be potentially lethal. Several clinical trials are ongoing to develop therapies for relapsed and refractory NHL, indicating growing interest in effective treatments.

Market Drivers

The NHL treatment market is primarily driven by high prevalence and aggressive nature of non-Hodgkin lymphomas. Many NHL types remain asymptomatic until advanced stages, necessitating early diagnosis and targeted therapies. Improved clinical outcomes and strong cure rates further drive the adoption of advanced therapeutics, particularly immunotherapies and targeted therapies.

Immunotherapy, for instance, has emerged as a novel and sophisticated therapeutic approach, offering targeted mechanisms that improve survival outcomes. Products like Yescarta by Kite Pharma/Gilead Sciences have contributed significantly to the segment's growth.

Additionally, the need for effective treatments for relapsed or refractory NHL cases has encouraged development and adoption of advanced therapies, boosting market growth.

Market Restraints

Despite growth, the market faces challenges from the high costs of advanced therapies, especially in emerging countries. Immunotherapies and CAR-T cell therapies are expensive, restricting access for a large portion of patients. Limited government reimbursement and absence of specialized payment schemes further restrain market expansion in developing regions.

Market Trends

Key market trends include increased R&D investments and launch of advanced therapeutics. Major companies are focusing on pipeline development, driven by the need for innovative therapies in aggressive and relapsed NHL cases. Sophisticated diagnostic techniques and early detection improve patient prognosis, which further promotes adoption of advanced treatment options.

Moreover, there is a growing interest in CAR-T cell therapies and personalized medicine approaches, reflecting a shift from conventional chemotherapy toward more precise, targeted, and immunotherapy-based interventions.

Segmentation Analysis

By Therapy Type:

  • Immunotherapy dominates with 57.45% share in 2026, generating USD 6.64 billion in 2025, supported by therapies like Yescarta.
  • Targeted therapies hold significant revenue due to precision and efficacy.
  • Chemotherapy remains standard treatment but contributes lower revenue due to generics.
  • Others include corticosteroids as supportive treatments.

By Disease Type:

  • B-cell lymphoma accounts for 87.04% of the market in 2026, reflecting its higher prevalence compared to T-cell lymphoma.
  • T-cell lymphoma remains comparatively rare, limiting its market contribution.

By Distribution Channel:

  • Hospital pharmacies dominate with 60.16% share in 2026, as most therapies require intravenous administration by trained professionals.
  • Retail pharmacies show moderate growth due to limited oral formulations.
  • Online pharmacies are emerging, driven by convenience and growing adoption of prescription services.

Regional Analysis

North America: Market size USD 5.72 billion in 2025, projected to reach USD 5.8 billion by 2026, driven by high awareness, prevalence, and adoption of advanced therapies.

Europe: Significant growth expected with CAGR of 8.0%, UK market USD 0.55 billion and Germany USD 0.81 billion by 2026. New therapeutics like CAR-T cell therapies support market expansion.

Asia-Pacific: Rapid growth anticipated due to regulatory approvals and large patient base. Japan market USD 900.9 million in 2025, projected USD 0.99 billion by 2026, China USD 0.73 billion, India USD 0.34 billion by 2026.

Rest of World: Latin America and Middle East & Africa are nascent markets but increasing healthcare expenditure and awareness is expected to drive demand for advanced therapies.

Competitive Landscape

The NHL treatment market is highly competitive. Key players include Novartis AG, Gilead Sciences/Kite Pharma, Takeda, AstraZeneca, Bayer AG, Bristol Myers Squibb, Genentech, among others. Companies focus on advanced therapies such as immunotherapy, CAR-T, and targeted therapies. Emerging players like Spectrum Pharmaceuticals are expanding market presence through innovative therapeutics and pipeline development.

Recent Developments:

  • Feb 2021: Bristol Myers Squibb received FDA approval for CAR-T therapy Breyanzi for relapsed/refractory large B-cell lymphoma.
  • Dec 2020: AstraZeneca's Calquence showed positive Phase 2 results for mantle cell lymphoma.
  • June 2020: Kyowa Kirin launched POTELIGO for rare lymphomas in Germany.

Conclusion

The global non-Hodgkin lymphoma treatment market is projected to grow from USD 11.59 billion in 2025 to USD 19.44 billion by 2034, at a CAGR of 6.25%. Market growth is driven by the high prevalence of NHL, need for targeted therapies, rising adoption of immunotherapies, and ongoing R&D. While high therapy costs and limited access in emerging countries present challenges, expanding clinical pipelines, regulatory approvals, and increasing awareness are expected to sustain market growth across North America, Europe, and Asia-Pacific.

Segmentation By Therapy

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Others

By Disease Type

  • B-cell Lymphoma
  • T-cell Lymphoma

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia-Pacific)
  • Latin America (Brazil, Mexico, and the Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and the Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Lymphoma - by Key Countries - 2025
  • 4.2. Pipeline Analysis
  • 4.3. Key Industry Developments
  • 4.4. Regulatory Scenario, by Key Regions
  • 4.5. Analysis of Economic Burden of Non-Hodgkin Lymphoma
  • 4.6. New Product Launches
  • 4.7. Overview of Emerging Treatments for Non-Hodgkin Lymphoma

5. Global Non-Hodgkin Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Therapy
    • 5.2.1. Immunotherapy
    • 5.2.2. Targeted Therapy
    • 5.2.3. Chemotherapy
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Disease Type
    • 5.3.1. B-cell Lymphoma
    • 5.3.2. T-cell Lymphoma
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies & Drug Stores
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Non-Hodgkin Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Therapy
    • 6.2.1. Immunotherapy
    • 6.2.2. Targeted Therapy
    • 6.2.3. Chemotherapy
    • 6.2.4. Others
  • 6.3. Market Analysis - By Disease Type
    • 6.3.1. B-cell Lymphoma
    • 6.3.2. T-cell Lymphoma
  • 6.4. Market Analysis - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies & Drug Stores
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Non-Hodgkin Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Therapy
    • 7.2.1. Immunotherapy
    • 7.2.2. Targeted Therapy
    • 7.2.3. Chemotherapy
    • 7.2.4. Others
  • 7.3. Market Analysis - By Disease Type
    • 7.3.1. B-cell Lymphoma
    • 7.3.2. T-cell Lymphoma
  • 7.4. Market Analysis - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies & Drug Stores
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis - By Country/ sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Non-Hodgkin Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Therapy
    • 8.2.1. Immunotherapy
    • 8.2.2. Targeted Therapy
    • 8.2.3. Chemotherapy
    • 8.2.4. Others
  • 8.3. Market Analysis - By Disease Type
    • 8.3.1. B-cell Lymphoma
    • 8.3.2. T-cell Lymphoma
  • 8.4. Market Analysis - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies & Drug Stores
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis - By Country/ sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Non-Hodgkin Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Therapy
    • 9.2.1. Immunotherapy
    • 9.2.2. Targeted Therapy
    • 9.2.3. Chemotherapy
    • 9.2.4. Others
  • 9.3. Market Analysis - By Disease Type
    • 9.3.1. B-cell Lymphoma
    • 9.3.2. T-cell Lymphoma
  • 9.4. Market Analysis - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies & Drug Stores
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis - By Country/ sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis - By Therapy
    • 10.2.1. Immunotherapy
    • 10.2.2. Targeted Therapy
    • 10.2.3. Chemotherapy
    • 10.2.4. Others
  • 10.3. Market Analysis - By Disease Type
    • 10.3.1. B-cell Lymphoma
    • 10.3.2. T-cell Lymphoma
  • 10.4. Market Analysis - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies & Drug Stores
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis - By Country/ sub-region
    • 10.5.1. GCC Countries
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Competition Dashboard
  • 11.4. Comparative Analysis - Major Players
  • 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.5.1. Takeda Pharmaceutical Company Limited
      • 11.5.1.1. Overview,
      • 11.5.1.2. Products & services,
      • 11.5.1.3. SWOT analysis,
      • 11.5.1.4. Recent developments,
      • 11.5.1.5. strategies,
      • 11.5.1.6. financials (based on availability)
    • 11.5.2. AstraZeneca
      • 11.5.2.1. Overview,
      • 11.5.2.2. Products & services,
      • 11.5.2.3. SWOT analysis,
      • 11.5.2.4. Recent developments,
      • 11.5.2.5. strategies,
      • 11.5.2.6. financials (based on availability)
    • 11.5.3. Bayer AG
      • 11.5.3.1. Overview,
      • 11.5.3.2. Products & services,
      • 11.5.3.3. SWOT analysis,
      • 11.5.3.4. Recent developments,
      • 11.5.3.5. strategies,
      • 11.5.3.6. financials (based on availability)
    • 11.5.4. Novartis AG
      • 11.5.4.1. Overview,
      • 11.5.4.2. Products & services,
      • 11.5.4.3. SWOT analysis,
      • 11.5.4.4. Recent developments,
      • 11.5.4.5. strategies,
      • 11.5.4.6. financials (based on availability)
    • 11.5.5. Spectrum Pharmaceuticals, Inc.
      • 11.5.5.1. Overview,
      • 11.5.5.2. Products & services,
      • 11.5.5.3. SWOT analysis,
      • 11.5.5.4. Recent developments,
      • 11.5.5.5. strategies,
      • 11.5.5.6. financials (based on availability)
    • 11.5.6. Bristol Myers Squibb Company
      • 11.5.6.1. Overview,
      • 11.5.6.2. Products & services,
      • 11.5.6.3. SWOT analysis,
      • 11.5.6.4. Recent developments,
      • 11.5.6.5. strategies,
      • 11.5.6.6. financials (based on availability)
    • 11.5.7. Janssen Pharmaceuticals, Inc.
      • 11.5.7.1. Overview,
      • 11.5.7.2. Products & services,
      • 11.5.7.3. SWOT analysis,
      • 11.5.7.4. Recent developments,
      • 11.5.7.5. strategies,
      • 11.5.7.6. financials (based on availability)
    • 11.5.8. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
      • 11.5.8.1. Overview,
      • 11.5.8.2. Products & services,
      • 11.5.8.3. SWOT analysis,
      • 11.5.8.4. Recent developments,
      • 11.5.8.5. strategies,
      • 11.5.8.6. financials (based on availability)
    • 11.5.9. Merck & Co., Inc.
      • 11.5.9.1. Overview,
      • 11.5.9.2. Products & services,
      • 11.5.9.3. SWOT analysis,
      • 11.5.9.4. Recent developments,
      • 11.5.9.5. strategies,
      • 11.5.9.6. financials (based on availability)
    • 11.5.10. Spectrum Pharmaceuticals, Inc.
      • 11.5.10.1. Overview,
      • 11.5.10.2. Products & services,
      • 11.5.10.3. SWOT analysis,
      • 11.5.10.4. Recent developments,
      • 11.5.10.5. strategies,
      • 11.5.10.6. financials (based on availability)
    • 11.5.11. Other Prominent Players
      • 11.5.11.1. Overview,
      • 11.5.11.2. Products & services,
      • 11.5.11.3. SWOT analysis,
      • 11.5.11.4. Recent developments,
      • 11.5.11.5. strategies,
      • 11.5.11.6. financials (based on availability)

12. Strategic Recommendations

List of Tables

  • Table 1: Global Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Therapy, 2015-2034
  • Table 2: Global Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2015-2034
  • Table 3: Global Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2015-2034
  • Table 4: Global Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 5: North America Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Therapy, 2021-2034
  • Table 6: North America Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
  • Table 7: North America Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 9: Europe Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Therapy, 2021-2034
  • Table 10: Europe Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
  • Table 11: Europe Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Therapy, 2021-2034
  • Table 14: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
  • Table 15: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Therapy, 2021-2034
  • Table 18: Latin America Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
  • Table 19: Latin America Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Therapy, 2021-2034
  • Table 22: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
  • Table 23: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Non-Hodgkin Lymphoma Treatment Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
  • Figure 2: Global Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Therapy, 2025 & 2034
  • Figure 3: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by Immunotherapy, 2021-2034
  • Figure 4: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by Targeted Therapy, 2021-2034
  • Figure 5: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by Chemotherapy, 2021-2034
  • Figure 6: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 7: Global Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Disease Type, 2025 & 2034
  • Figure 8: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by B-cell Lymphoma, 2021-2034
  • Figure 9: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by T-cell Lymphoma, 2021-2034
  • Figure 10: Global Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 11: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by Hospital Pharmacies, 2021-2034
  • Figure 12: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by Retail Pharmacies & Drug Stores, 2021-2034
  • Figure 13: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by Online Pharmacies, 2021-2034
  • Figure 14: Global Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Region, 2025 & 2034
  • Figure 15: North America Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Therapy, 2025 & 2034
  • Figure 16: North America Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Therapy, 2025
  • Figure 17: North America Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 18: North America Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 19: North America Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 20: North America Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 21: North America Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), By Country, 2025 & 2034
  • Figure 22: North America Non-Hodgkin Lymphoma Treatment Market Value Share (%), By Country, 2025
  • Figure 23: Europe Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Therapy, 2025 & 2034
  • Figure 24: Europe Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Therapy, 2025
  • Figure 25: Europe Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 26: Europe Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 27: Europe Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 28: Europe Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 29: Europe Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 30: Europe Non-Hodgkin Lymphoma Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 31: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Therapy, 2025 & 2034
  • Figure 32: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Therapy, 2025
  • Figure 33: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 34: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 35: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 36: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 37: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 38: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 39: Latin America Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Therapy, 2025 & 2034
  • Figure 40: Latin America Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Therapy, 2025
  • Figure 41: Latin America Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 42: Latin America Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 43: Latin America Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Non-Hodgkin Lymphoma Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Therapy, 2025 & 2034
  • Figure 48: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Therapy, 2025
  • Figure 49: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 50: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 51: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 52: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 53: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 54: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 55: Global Non-Hodgkin Lymphoma Treatment Market Share (%), By Company, 2025